Literature DB >> 16775224

The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses.

S Farzana Hussain1, David Yang, Dima Suki, Kenneth Aldape, Elizabeth Grimm, Amy B Heimberger.   

Abstract

Little is known about the immune performance and interactions of CNS microglia/macrophages in glioma patients. We found that microglia/macrophages were the predominant immune cell infiltrating gliomas ( approximately 1% of total cells); others identified were myeloid dendritic cells (DCs), plasmacytoid DCs, and T cells. We isolated and analyzed the immune functions of CD11b/c+CD45+ glioma-infiltrating microglia/macrophages (GIMs) from postoperative tissue specimens of glioma patients. Although GIMs expressed substantial levels of Toll-like receptors (TLRs), they did not appear stimulated to produce pro-inflammatory cytokines (tumor necrosis factor alpha, interleukin 1, or interleukin 6), and in vitro, lipopolysaccharides could bind TLR-4 but could not induce GIM-mediated T-cell proliferation. Despite surface major histocompatibility complex class II expression, they lacked expression of the costimulatory molecules CD86, CD80, and CD40 critical for T-cell activation. Ex vivo, we demonstrate a corresponding lack of effector/activated T cells, as glioma-infiltrating CD8+ T cells were phenotypically CD8+CD25-. By contrast, there was a prominent population of regulatory CD4 T cells (CD4+CD25+FOXP3+) infiltrating the tumor. We conclude that while GIMs may have a few intact innate immune functions, their capacity to be stimulated via TLRs, secrete cytokines, upregulate costimulatory molecules, and in turn activate antitumor effector T cells is not sufficient to initiate immune responses. Furthermore, the presence of regulatory T cells may also contribute to the lack of effective immune activation against malignant human gliomas.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16775224      PMCID: PMC1871955          DOI: 10.1215/15228517-2006-008

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  72 in total

1.  CD4 T cell anergy in murine AIDS: costimulation via CD28 and the addition of IL-12 are not sufficient to rescue anergic CD4 T cells.

Authors:  C Andrews; S L Swain; G Muralidhar
Journal:  J Immunol       Date:  1997-09-01       Impact factor: 5.422

2.  Cutting edge: human CD4+CD25+ T cells restrain the maturation and antigen-presenting function of dendritic cells.

Authors:  Namita Misra; Jagadeesh Bayry; Sébastien Lacroix-Desmazes; Michel D Kazatchkine; Srini V Kaveri
Journal:  J Immunol       Date:  2004-04-15       Impact factor: 5.422

3.  Similar ligand densities required for restimulation and effector function of cytotoxic T cells.

Authors:  A Oxenius; M F Bachmann
Journal:  Cell Immunol       Date:  1997-07-10       Impact factor: 4.868

4.  Inhibition of microglial cell RANTES production by IL-10 and TGF-beta.

Authors:  S Hu; C C Chao; L C Ehrlich; W S Sheng; R L Sutton; G L Rockswold; P K Peterson
Journal:  J Leukoc Biol       Date:  1999-06       Impact factor: 4.962

5.  Microglial/macrophage expression of interleukin 10 in human glioblastomas.

Authors:  S Wagner; S Czub; M Greif; G H Vince; N Süss; S Kerkau; P Rieckmann; W Roggendorf; K Roosen; J C Tonn
Journal:  Int J Cancer       Date:  1999-07-02       Impact factor: 7.396

Review 6.  Does the immune system see tumors as foreign or self?

Authors:  Drew Pardoll
Journal:  Annu Rev Immunol       Date:  2001-12-19       Impact factor: 28.527

7.  Differential expression of MHC class II and B7 costimulatory molecules by microglia in rodent gliomas.

Authors:  Behnam Badie; Becky Bartley; Jill Schartner
Journal:  J Neuroimmunol       Date:  2002-12       Impact factor: 3.478

8.  Activation requirements for the induction of CD4+CD25+ T cell suppressor function.

Authors:  Angela M Thornton; Ciriaco A Piccirillo; Ethan M Shevach
Journal:  Eur J Immunol       Date:  2004-02       Impact factor: 5.532

9.  Cutting edge: cross-presentation as a mechanism for efficient recruitment of tumor-specific CTL to the brain.

Authors:  Thomas Calzascia; Wilma Di Berardino-Besson; Rick Wilmotte; Frédérick Masson; Nicolas de Tribolet; Pierre-Yves Dietrich; Paul R Walker
Journal:  J Immunol       Date:  2003-09-01       Impact factor: 5.422

10.  Role for CD4(+) CD25(+) regulatory T cells in reactivation of persistent leishmaniasis and control of concomitant immunity.

Authors:  Susana Mendez; Stacie K Reckling; Ciriacco A Piccirillo; David Sacks; Yasmine Belkaid
Journal:  J Exp Med       Date:  2004-07-19       Impact factor: 14.307

View more
  256 in total

1.  Intratumoral mediated immunosuppression is prognostic in genetically engineered murine models of glioma and correlates to immunotherapeutic responses.

Authors:  Ling-Yuan Kong; Adam S Wu; Tiffany Doucette; Jun Wei; Waldemar Priebe; Gregory N Fuller; Wei Qiao; Raymond Sawaya; Ganesh Rao; Amy B Heimberger
Journal:  Clin Cancer Res       Date:  2010-10-04       Impact factor: 12.531

Review 2.  Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma?

Authors:  Amy B Heimberger; John H Sampson
Journal:  Neuro Oncol       Date:  2010-12-10       Impact factor: 12.300

3.  CD8+ T-cell infiltrate in newly diagnosed glioblastoma is associated with long-term survival.

Authors:  Isaac Yang; Tarik Tihan; Seunggu J Han; Margaret R Wrensch; John Wiencke; Michael E Sughrue; Andrew T Parsa
Journal:  J Clin Neurosci       Date:  2010-08-19       Impact factor: 1.961

4.  Anti-PD-1 Induces M1 Polarization in the Glioma Microenvironment and Exerts Therapeutic Efficacy in the Absence of CD8 Cytotoxic T Cells.

Authors:  Ganesh Rao; Khatri Latha; Martina Ott; Aria Sabbagh; Anantha Marisetty; Xiaoyang Ling; Daniel Zamler; Tiffany A Doucette; Yuhui Yang; Ling-Yuan Kong; Jun Wei; Gregory N Fuller; Fernando Benavides; Adam M Sonabend; James Long; Shulin Li; Michael Curran; Amy B Heimberger
Journal:  Clin Cancer Res       Date:  2020-06-18       Impact factor: 12.531

Review 5.  The Gut-Brain Axis, Paving the Way to Brain Cancer.

Authors:  Ruty Mehrian-Shai; Juergen K V Reichardt; Curtis C Harris; Amos Toren
Journal:  Trends Cancer       Date:  2019-03-16

6.  VSIG4 is highly expressed and correlated with poor prognosis of high-grade glioma patients.

Authors:  Tao Xu; Ying Jiang; Yong Yan; Hongxiang Wang; Chengyin Lu; Hanchong Xu; Weiqing Li; Da Fu; Yicheng Lu; Juxiang Chen
Journal:  Am J Transl Res       Date:  2015-06-15       Impact factor: 4.060

Review 7.  TLR-4 Signaling vs. Immune Checkpoints, miRNAs Molecules, Cancer Stem Cells, and Wingless-Signaling Interplay in Glioblastoma Multiforme-Future Perspectives.

Authors:  Jakub Litak; Cezary Grochowski; Joanna Litak; Ida Osuchowska; Krzysztof Gosik; Elżbieta Radzikowska; Piotr Kamieniak; Jacek Rolinski
Journal:  Int J Mol Sci       Date:  2020-04-28       Impact factor: 5.923

8.  Blockade of CD73 delays glioblastoma growth by modulating the immune environment.

Authors:  J H Azambuja; R S Schuh; L R Michels; I C Iser; L R Beckenkamp; G G Roliano; G S Lenz; J N Scholl; J Sévigny; M R Wink; M A Stefani; A M O Battastini; F Figueiró; H F Teixeira; E Braganhol
Journal:  Cancer Immunol Immunother       Date:  2020-04-29       Impact factor: 6.968

Review 9.  Is HCMV a tumor promoter?

Authors:  Liliana Soroceanu; Charles S Cobbs
Journal:  Virus Res       Date:  2010-10-29       Impact factor: 3.303

10.  Bone marrow derived myeloid cells orchestrate antiangiogenic resistance in glioblastoma through coordinated molecular networks.

Authors:  B R Achyut; Adarsh Shankar; A S M Iskander; Roxan Ara; Kartik Angara; Peng Zeng; Robert A Knight; Alfonso G Scicli; Ali S Arbab
Journal:  Cancer Lett       Date:  2015-09-21       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.